Adjuvants, Immunologic

• 

  Subject Areas on Research

  • A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. 
  • A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. 
  • A comparison of non-toxin vaccine adjuvants for their ability to enhance the immunogenicity of nasally-administered anthrax recombinant protective antigen. 
  • A crucial role of L-selectin in C protein-induced experimental polymyositis in mice. 
  • A global approach to tumor immunology. 
  • A need for effective adjuvants. 
  • A novel neurotoxoid vaccine prevents mucosal botulism. 
  • A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. 
  • A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination. 
  • A self-adjuvanting supramolecular vaccine carrying a folded protein antigen. 
  • A self-assembling peptide acting as an immune adjuvant. 
  • A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. 
  • Acidic stimuli activates two distinct pathways in taste receptor cells from rat fungiform papillae. 
  • Activated lymphocytes promote endothelial cell detachment from matrix: a role for modulation of endothelial cell beta 1 integrin affinity. 
  • Activin A and follistatin are dynamically regulated during human pregnancy. 
  • Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. 
  • Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques. 
  • Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. 
  • Alpha 2-macroglobulin binds CpG oligodeoxynucleotides and enhances their immunostimulatory properties by a receptor-dependent mechanism. 
  • Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen. 
  • Altered immune responses in apolipoprotein E-deficient mice. 
  • An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. 
  • Antioxidants suppress mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE). 
  • Bisphosphonates target B cells to enhance humoral immune responses. 
  • Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial. 
  • C1q enhances the phagocytosis of Cryptococcus neoformans blastospores by human monocytes. 
  • CD40 expression by human fibroblasts. 
  • CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus (SIV) vaccine enhances protection against neutralization-resistant mucosal SIV infection. 
  • CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge. 
  • CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. 
  • Capric acid and hydroxypropylmethylcellulose increase the immunogenicity of nasally administered peptide vaccines. 
  • Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine. 
  • Chemokine-adjuvanted electroporated DNA vaccine induces substantial protection from simian immunodeficiency virus vaginal challenge. 
  • Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3. 
  • Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. 
  • Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with non-replicating antigens. 
  • Clinical applications of dendritic cell vaccines. 
  • Clinical intestinal transplantation: new perspectives and immunologic considerations. 
  • Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. 
  • Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects. 
  • Codelivery of Envelope Protein in Alum with MVA Vaccine Induces CXCR3-Biased CXCR5+ and CXCR5- CD4 T Cell Responses in Rhesus Macaques. 
  • Comparison of immunogenicity, efficacy and transcriptome changes of inactivated rabies virus vaccine with different adjuvants. 
  • Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis. 
  • Control of Heterologous Simian Immunodeficiency Virus SIVsmE660 Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques. 
  • Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. 
  • Current and future treatment of HIV infection. 
  • Current management of pediatric inflammatory bowel disease. 
  • Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression. 
  • Cysteine-tailed class I-binding peptides bind to CpG adjuvant and enhance primary CTL responses. 
  • Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. 
  • Cytokines: the future of intranasal vaccine adjuvants. 
  • DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA. 
  • DNA and protein co-immunization improves the magnitude and longevity of humoral immune responses in macaques. 
  • DNA prime/protein boost vaccination elicits robust humoral response in rhesus macaques using oligomeric simian immunodeficiency virus envelope and Advax delta inulin adjuvant. 
  • DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers. 
  • DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory. 
  • DNA-MVA-protein vaccination of rhesus macaques induces HIV-specific immunity in mucosal-associated lymph nodes and functional antibodies. 
  • Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. 
  • Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity. 
  • Distant cutaneous granulomas after bacille Calmette-Guérin immunotherapy for malignant melanoma: case for direct infection. 
  • Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. 
  • Effect of particulate adjuvant on the anthrax protective antigen dose required for effective nasal vaccination. 
  • Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1. 
  • Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. 
  • Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d. 
  • Enhancing immunogenicity by CpG DNA. 
  • GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. 
  • Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy. 
  • Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant. 
  • HIV immunization. Fresh pathways to follow. 
  • HIV vaccine development at Duke University Medical Center. 
  • HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine. 
  • Host response to infection: the role of CpG DNA in induction of cyclooxygenase 2 and nitric oxide synthase 2 in murine macrophages. 
  • Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. 
  • Hyperimmune human IgG or recombinant human granulocyte-macrophage colony-stimulating factor as adjunctive therapy for group B streptococcal sepsis in newborn rats. 
  • IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens. 
  • IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques. 
  • IL-1R type I-dependent hemopoietic stem cell proliferation is necessary for inflammatory granulopoiesis and reactive neutrophilia. 
  • Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40. 
  • Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking. 
  • Immune reconstitution syndrome associated with opportunistic mycoses. 
  • Immune responses to DNA in normal and aberrant immunity. 
  • Immunization of rabbits with highly purified, soluble, trimeric human immunodeficiency virus type 1 envelope glycoprotein induces a vigorous B cell response and broadly cross-reactive neutralization. 
  • Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. 
  • Immunization with the Haemophilus ducreyi hemoglobin receptor HgbA with adjuvant monophosphoryl lipid A protects swine from a homologous but not a heterologous challenge. 
  • Immunization with the Haemophilus ducreyi trimeric autotransporter adhesin DsrA with alum, CpG or imiquimod generates a persistent humoral immune response that recognizes the bacterial surface. 
  • Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial. 
  • Immunomodulatory peptides with high binding affinity for class II MHC molecules for the prevention of graft-versus-host disease. 
  • Immunotherapeutic agents for the management of BCG refractory non-muscle invasive bladder cancer. 
  • Immunotherapy of malignant brain tumors. 
  • Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques. 
  • Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF. 
  • Inducible expression of the alpha2-macroglobulin signaling receptor in response to antigenic stimulation: a study of second messenger generation. 
  • Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. 
  • Inhibition of murine macrophage IL-12 production by natural and synthetic DNA. 
  • Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. 
  • Interferon-beta1A-induced polyarthritis in a patient with the HLA-DRB1*0404 allele. 
  • Intra-seasonal antibody repertoire analysis of a subject immunized with an MF59®-adjuvanted pandemic 2009 H1N1 vaccine. 
  • Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. 
  • Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue. 
  • Intravesical therapy use in the high risk patient: practice patterns in an equal access healthcare institution before and after national guidelines. 
  • Investigational therapies for non-muscle invasive bladder cancer. 
  • Leptin selectively augments thymopoiesis in leptin deficiency and lipopolysaccharide-induced thymic atrophy. 
  • Leukocyte rolling velocities and migration are optimized by cooperative L-selectin and intercellular adhesion molecule-1 functions. 
  • Levamisole-induced vasculopathy: a report of 2 cases and a novel histopathologic finding. 
  • Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. 
  • Lyme disease vaccination: are we ready to try again? 
  • MNGIE neuropathy: five cases mimicking chronic inflammatory demyelinating polyneuropathy. 
  • Mast cell activators: a new class of highly effective vaccine adjuvants. 
  • Maximal adjuvant activity of nasally delivered IL-1α requires adjuvant-responsive CD11c(+) cells and does not correlate with adjuvant-induced in vivo cytokine production. 
  • Mechanisms of immune stimulation by bacterial DNA. 
  • Mesenchymal stem cells stimulate protective genetic reprogramming of injured cardiac ventricular myocytes. 
  • Microparticles as autoadjuvants in the pathogenesis of SLE. 
  • Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants. 
  • Modulation of HIV-1 immunity by adjuvants. 
  • Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. 
  • Mucosal and systemic adjuvant activity of alphavirus replicon particles. 
  • Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations. 
  • Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits. 
  • Mucosal vaccine targeting improves onset of mucosal and systemic immunity to botulinum neurotoxin A. 
  • Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials. 
  • Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. 
  • Nasal peptide vaccination elicits CD8 responses and reduces viral burden after challenge with virulent murine cytomegalovirus. 
  • New antifungal agents. 
  • Non-replicating mucosal and systemic vaccines: quantitative and qualitative differences in the Ag-specific CD8(+) T cell population in different tissues. 
  • Non-specific and specific active immunotherapy in a B16 murine melanoma system. 
  • Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination. 
  • Oral immunogenicity of the plant proteinase bromelain. 
  • Oral vaccine models: multiple delivery systems employing tetanus toxoid. 
  • Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. 
  • Potentiation of cell-mediated immune responses directed against P. falciparum sporozoite peptide vaccine by immunomodulators. 
  • Preclinical characterization of DUOC-01, a cell therapy product derived from banked umbilical cord blood for use as an adjuvant to umbilical cord blood transplantation for treatment of inherited metabolic diseases. 
  • Pregnancy and estradiol decrease GTPase activity in the guinea pig uterine artery. 
  • Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. 
  • Proinflammatory actions of thromboxane receptors to enhance cellular immune responses. 
  • Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration. 
  • QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. 
  • Re: Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. 
  • Role of the heat shock protein 90 in immune response stimulation by bacterial DNA and synthetic oligonucleotides. 
  • Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene. 
  • Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. 
  • Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. 
  • Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. 
  • Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. 
  • Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. 
  • Severely impaired B lymphocyte proliferation, survival, and induction of the c-Myc:Cullin 1 ubiquitin ligase pathway resulting from CD22 deficiency on the C57BL/6 genetic background. 
  • Single epitope mucosal vaccine delivered via immuno-stimulating complexes induces low level of immunity against simian-HIV. 
  • Skewed VH and V kappa gene family expression and pairing occurs among B lymphocytes in autoimmune motheaten mice. 
  • Specificity and immunochemical properties of anti-DNA antibodies induced in normal mice by immunization with mammalian DNA with a CpG oligonucleotide as adjuvant. 
  • Stable dry powder formulation for nasal delivery of anthrax vaccine. 
  • Stimulation of thymocyte proliferation by phosphorothioate DNA oligonucleotides. 
  • Strain-specific Plasmodium falciparum multifunctional CD4(+) T cell cytokine expression in Malian children immunized with the FMP2.1/AS02A vaccine candidate. 
  • Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer. 
  • Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. 
  • Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. 
  • Surface plasmon resonance measurements of plasma antibody avidity during primary and secondary responses to anthrax protective antigen. 
  • Surfactant protein A regulates complement activation. 
  • Swainsonine protects both murine and human haematopoietic systems from chemotherapeutic toxicity. 
  • Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes. 
  • Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys. 
  • Targeting the TLR9-MyD88 pathway in the regulation of adaptive immune responses. 
  • The Haemophilus ducreyi trimeric autotransporter adhesin DsrA protects against an experimental infection in the swine model of chancroid. 
  • The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines. 
  • The expression of plasma nucleosomes in mice undergoing in vivo apoptosis. 
  • The in vivo antiviral effect of CL246,738 is mediated by the independent induction of interferon-alpha and interferon-beta. 
  • The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen. 
  • The role of cpg sequences in the induction of anti-DNA antibodies. 
  • The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation. 
  • This paper is the winner of an SFB Award in the Hospital Intern, Residency category: Peptide biomaterials raising adaptive immune responses in wound healing contexts. 
  • Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects. 
  • Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study. 
  • Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV. 
  • Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques. 
  • Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells. 
  • Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines. 
  • Topical Imiquimod in the Treatment of Conjunctival Actinic Keratosis. 
  • Type B CpG oligodeoxynucleotides induce Th1 responses to peanut antigens: modulation of sensitization and utility in a truncated immunotherapy regimen in mice. 
  • Update on new immunomodulatory agents. 
  • Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein. 
  • Vaccination with Vaxfectin(®) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia. 
  • Vaccine adjuvants: Softness makes it better. 
  • Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: protection correlates with neutralizing antibody. 
  • When is an adjuvant not an adjuvant? Overview. 
  • [The effect of bromantane on the dopamin- and serotoninergic systems of the rat brain]. 
  • [The effect of bromantane, a new immunostimulant with psychostimulating action, on release and metabolism of dopamine in the dorsal striatum of freely moving rats: a microdialysis study]. 
• 

  Keywords of People

  • Cianciolo, George James, Associate Professor in Pathology, Pathology
  • Cunningham, Coleen Kathryn, Professor of Pediatrics, Pathology
  • Ferrari, Guido, Associate Professor of Surgery, Molecular Genetics and Microbiology
  • Gunn, Michael Dee, Professor of Medicine, Immunology
  • Jones, Nezzie, Student, Pathology
  • Lee, Walter T, Associate Professor of Surgery, Radiation Oncology
  • Staats, Herman Ford, Professor of Pathology, Immunology
  • Yang, Yiping, Professor of Medicine, Immunology
  • Zhong, Xiaoping, Professor of Pediatrics, Immunology